Indivior Pharmaceuticals Inc (INDV) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$39.60
Price Target
$44.67
Target Range
$36.00 — $50.00
Analyst Rating
Buy
Forward P/E12.7x
Trailing P/E24.1x
Forward PEG—
Implied Growth+60.9%
Median Target$48.00
Analyst Spread31.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$36
-9.1%
Consensus
$45
+12.8%
Bull Case
$50
+26.3%
INDV Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Indivior Pharmaceuticals Inc (INDV) has a Wall Street consensus price target of $44.67, based on estimates from 3 covering analysts. With the stock currently trading at $39.60, this represents a potential upside of +12.8%. The company has a market capitalization of $4.94B.
Analyst price targets range from a low of $36.00 to a high of $50.00, representing a 31% spread in expectations. The median target of $48.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, INDV trades at a trailing P/E of 24.1x and forward P/E of 12.7x. Analysts expect EPS to grow +60.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+51.3%
Avg Forward P/E16.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RBBNRibbon Communications Inc. | $472M | $2.69 | $3.50 | +30.1% | Buy | 20.7x | 8 |
 AVPTAvePoint, Inc. | $2.2B | $10.32 | $17.50 | +69.6% | Buy | 27.7x | 12 |
 BHVNBiohaven Ltd. | $1.0B | $9.73 | $21.29 | +118.7% | Buy | — | 25 |
 ALKSAlkermes plc | $5.9B | $35.40 | $44.00 | +24.3% | Buy | — | 28 |
 BHCBausch Health Companies Inc. | $2.1B | $5.72 | $8.00 | +39.7% | Buy | 1.3x | 38 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $52.28 | $60.00 | +14.8% | Buy | 24.1x | 14 |
 COLLCollegium Pharmaceutical, Inc. | $1.3B | $39.32 | $58.00 | +47.5% | Buy | 5.4x | 12 |
 MTLSMaterialise N.V. | $321M | $5.44 | $10.00 | +83.8% | Buy | 29.9x | 12 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 PCRXPacira BioSciences, Inc. | $930M | $23.64 | $29.50 | +24.8% | Hold | 8.6x | 36 |
Upside Potential Comparison
BHVNMTLSAVPTNKTRCOLLBHCRBBNPCRXSee INDV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INDV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INDV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINDV — Frequently Asked Questions
Quick answers to the most common questions about buying INDV stock.
What is the INDV stock price target for 2026?
Indivior Pharmaceuticals Inc (INDV) has a consensus 12-month price target of $44.67, implying 12.8% upside from $39.6. The 3 analysts covering INDV see moderate appreciation potential.
Is INDV a buy, sell, or hold?
INDV has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $44.67 implies 12.8% upside from current levels.
Is INDV stock overvalued or undervalued?
With a forward P/E of 12.6518x, INDV trades at a relatively low valuation. The consensus target of $44.67 implies 12.8% appreciation, suggesting meaningful undervaluation.
How high can INDV stock go?
The most bullish Wall Street analyst has a price target of $50 for INDV, while the most conservative target is $36. The consensus of $44.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover INDV stock?
INDV is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the INDV stock forecast?
The 12-month INDV stock forecast based on 3 Wall Street analysts shows a consensus price target of $44.67, with estimates ranging from $36 (bear case) to $50 (bull case). The median consensus rating is "Buy".
What is INDV's forward P/E ratio?
INDV trades at a forward P/E ratio of 12.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy INDV stock?
Wall Street analysts are optimistic on INDV, with a "Buy" consensus rating and $44.67 price target (12.8% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do INDV price targets vary so much?
INDV analyst price targets range from $36 to $50, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.67 consensus represents the middle ground.